Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Gross Profit (2024 - 2025)

Autolus Therapeutics (AUTL) has disclosed Gross Profit for 2 consecutive years, with -$7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit changed N/A year-over-year to -$7.4 million, compared with a TTM value of -$31.3 million through Sep 2025, changed N/A, and an annual FY2024 reading of -$1.3 million, down 174.62% over the prior year.
  • Gross Profit was -$7.4 million for Q3 2025 at Autolus Therapeutics, down from -$3.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $10.1 million in Q1 2024 and bottomed at -$11.4 million in Q4 2024.